Samuel Constant
Overview
Explore the profile of Samuel Constant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
966
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Avila R, Muller I, Barlow H, Middleton A, Theiventhran M, Basili D, et al.
Front Toxicol
. 2025 Mar;
7:1426132.
PMID: 40061084
Introduction: This work evaluated a non-animal toolbox to be used within a next-generation risk assessment (NGRA) framework to assess chemical-induced lung effects using human upper and lower respiratory tract models,...
2.
Esteban Enjuto L, Taty Poaty V, Bouveret M, Song H, Constant S, Patarin J
Sci Rep
. 2024 Dec;
14(1):31660.
PMID: 39738355
Pulmonary mucus serves as a crucial protective barrier in the respiratory tract, defending against pathogens and contributing to effective clearance mechanisms. In Muco Obstructive Pulmonary Diseases (MOPD), abnormal rheological properties...
3.
Zwygart A, Medaglia C, Zhu Y, Bart Tarbet E, Jonna W, Fage C, et al.
J Med Virol
. 2024 Dec;
96(12):e70101.
PMID: 39620346
In recent decades, epidemics and pandemics have multiplied throughout the world, with viruses generally being the primary responsible agents. Among these, influenza viruses play a key role, as they potentially...
4.
Siegrist D, Jonsdottir H, Bouveret M, Boda B, Constant S, Engler O
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458594
The emergence, global spread, and persistence of SARS-CoV-2 resulted in an unprecedented need for effective antiviral drugs. Throughout the pandemic, various drug development and treatment strategies were adopted, including repurposing...
5.
Sharma M, Huber E, Arnesdotter E, Behrsing H, Bettmann A, Brandwein D, et al.
Arch Toxicol
. 2024 Oct;
99(1):57-66.
PMID: 39365315
Standard information reporting helps to ensure that assay conditions and data are consistently reported and to facilitate inter-laboratory comparisons. Here, we present recommendations on minimum information for reporting on the...
6.
Paull J, Luscombe C, Seta A, Heery G, Bobardt M, Gallay P, et al.
Sci Rep
. 2024 Sep;
14(1):21259.
PMID: 39261670
COVID-19 remains a severe condition for many including immunocompromised individuals. There remains a need for effective measures against this and other respiratory infections, which transmit via virus-laden droplets that reach...
7.
Do T, Abdelnabi R, Boda B, Constant S, Neyts J, Jochmans D
Antiviral Res
. 2024 Sep;
231:105994.
PMID: 39237005
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven key in the successful treatment of infections with HIV and HCV. For the treatment of infections...
8.
Bondeelle L, Huang S, Constant S, Clement S, Salmona M, Le Goff J, et al.
Pharmacol Res Perspect
. 2024 Aug;
12(5):e1242.
PMID: 39210688
Cyclosporin A (CsA), an immunosuppressive drug used in transplant recipients, inhibits graft rejection by binding to cyclophilins and competitively inhibiting calcineurin. While concerns about respiratory infections in immunosuppressed patients exist,...
9.
Barbot A, Lheritier-Barrand M, Murrieta-Aguttes M, Leonetti M, Vernaz J, Huang S, et al.
Front Pharmacol
. 2024 Jun;
15:1393702.
PMID: 38933682
Background: Fexofenadine (FEX) is an antihistamine that acts as an inverse agonist against histamine (HIS) receptor 1 (H1R), which mediates the allergic reaction. Inverse agonists may be more potent than...
10.
Do T, Abdelnabi R, Boda B, Constant S, Neyts J, Jochmans D
bioRxiv
. 2024 May;
PMID: 38798406
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven a key in the successful treatment of infections with HIV and HCV. For the treatment of...